Lipoxin A4 increases survival by decreasing systemic inflammation and bacterial load in sepsis

Shock

Volumn 36, Issue 4, 2011, Pages 410-416

  Walker, Jean ^a   Dichter, Eric ^a   Lacorte, Grace ^a   Kerner, David ^a   Spur, Bernd ^a   Rodriguez, Ana ^a   Yin, Kingsley ^a  

^a UMDNJ School of Osteopathic Medicine   (United States)

Author keywords

CLP; macrophages; NF B; phagocytosis; resolution; survival

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; LIPOXIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL LOAD; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MODEL; EXPERIMENTAL LIGATION; HOST RESISTANCE; INFLAMMATION; MALE; NONHUMAN; PERITONEUM MACROPHAGE; RAT; SEPSIS; TISSUE INJURY;

ANIMALS; BACTERIAL LOAD; CHEMOKINE CCL2; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; LIPOXINS; MALE; NF-KAPPA B; PHAGOCYTOSIS; RATS; RATS, SPRAGUE-DAWLEY; SEPSIS;

EID: 80052965033     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31822798c1     Document Type: Article

References (35)

1. Annane D, Bellissant E, Cavallion JM: Septic shock. Lancet 365:63-78, 2005.
2. Ayala A, Perrin MM, Kisala JM, Ertel W, Chaudry IH: Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (IL-1, IL-6 and TNF). Circ Shock 36(3):191-199, 1992.
3. Muenzer JT, Davis CG, Dunne BS, Unsinger J, Dunne WM, Hotchkiss RS: Pneumonia after cecal ligation and puncture: a clinically relevant Btwo-hit[ model of sepsis. Shock 26(6):565-570, 2006. (Pubitemid 44789629)
4. Murphey ED, Lin CY, McGuire RW, Toliver-Kinsky T, Herndon DN, Sherwood ER: Diminished bacterial clearance is associated with decreased IL-12 and interferon-+ production but a sustained proinflammatory response in a murine model of postseptic immunosuppression. Shock 21(5):415-425, 2004.
5. Serhan CN, Chiang N, Van Dyke TE: Resolving inflammation: dual antiinflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8:349-361, 2008. (Pubitemid 351595216)
6. Lee TH, Horton CE, Kyan-Aung U, Haskard D, Crea AE, Spur BW: Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methionylYL-leucylYL-leucylYL-phenylalanine. Clin Sci (Lond) 77:195-203, 1989. (Pubitemid 19203563)
7. Mitchell S, Thomas G, Harvey K, Cottell D, Reville K, Berlasconi G, Petasis NA, Erwig L, Rees AJ, Savill J, et al.: Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 13:2497-2507, 2002.
8. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, Suramanyam B, Guilford WJ, et al.: A "-oxidationY resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci USA 101:15736-15741, 2004. (Pubitemid 39473557)
9. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams IR, Neish AS, Madara JL: Lipoxin A4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfateYinduced colitis. J Immunol 168:5260-5267, 2002. (Pubitemid 34495994)
10. Bafica A Scanga CA Serhan C Machado F White S Sher A Aliberti J: Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenaseYdependent lipoxin production. J Clin Invest 115(6):1601-1606, 2005. (Pubitemid 40814668)
11. Aliberti J, Serhan C, Sher A: Parasite-induced lipoxin A4 is an endogenous regulator of IL-12 production and immunopathology in Toxoplasma gondii infection. J Exp Med 196(9):1253-1262, 2002. (Pubitemid 35304190)
12. Rodŕguez A, Nomen M, Spur BW, Godfroid JJ, Lee TH: Total synthesis of lipoxin A4 and lipoxin B4 from butadiene. Tetrahedron Lett 41:823-826, 2000.
13. Yin K, Hock CE, Lai P-S, Ross JT, Yue G: Role of interferon-gamma in lung inflammation following cecal ligation and puncture in rats. Shock 12(3):215-221, 1999.
14. Muenzer JT, Davis CG, Chang K, Schmidt RE, Dunne WM, Coopersmith CM, Hotchkiss RS: Characterization and modulation of the immunosuppressive phase of sepsis. Infect Immun 78(4):1582-1592, 2010.
15. Bannenberg G, Moussignac RL, Gronert K, Devchand RR, Schmidt BA, Guilford WJ, Bauman JG, Subramanyam B, Perez HD, Parkinson JF, et al.: Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143:43-52, 2004. (Pubitemid 39280023)
16. Friedland JS, Porter JC, Daryanani S, Bland JM, Streaton NJ, Vesely MJ, Griffin GE, Bennett ED, Remick DG: Plasma proinflammatory cytokine concentrations, Acute Physiology and Chronic Health Evaluation (APACHE) III scores and survival in patients in an intensive care unit. Crit Care Med 24: 1775-1781, 1996. (Pubitemid 26382917)
17. Remick DG, Bolgos G, Copeland S, Siddiqui J: Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect Immun 73:2751-2757, 2005. (Pubitemid 40570341)
18. Bozza FA, Salluh JI, Japiassu AM, Soares M, Assis EF, Gomes RN, Bozza MT, Castro-Faria-Neto HC, Bozza PT: Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Critical Care 11(2):R49, 2007.
19. Souza DG, Fagundes CT, Amaral FA, Cisalpino D, Sousa LP, Vieira AT, Pinho V, Nicoli JR, Vieira LQ, Fierro IM, et al.: The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 179(12):8533-8543, 2007.
20. Mattioli I, Sebald A, Bucher C, Charles E-P, Nakano H, Doi T, Kracht M, Schmitz ML: Transient and selective NF-.B p65 serine 536 phosphorylation induced by T cell costimulation is mediated by I.B kinase b and controls the kinetics of p65 nuclear import. J Immunol 172:6336-6344, 2004. (Pubitemid 38621242)
21. Sakurai H, Chiba H, Miyoshi H, Sugita T, Toriumi W: IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274(43):30353-30356, 1999.
22. Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, Schmitz ML: Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J Biol Chem 281(10):6175-6183, 2006. (Pubitemid 43847547)
23. Lenz AM, Franklin GA, Fairweather M, McClintock ML, Jaia VR, Peyton JC, Gardner SA, Cheadle WG: Endogenous IL-10 leads to impaired bacterial clearance and reduced survival in a murine model of chronic peritonitis. Cytokine 40(3):207-215, 2007. (Pubitemid 350213433)
24. Shin HH, Lee JE, Choi HS: Absence of 4-1BB increases cell influx into the peritoneal cavity in response to LPS stimulation by decreasing macrophage IL-10 levels. FEBS Letters 581(22):4355-4360, 2007.
25. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, Swan R, Kherouf H, Monnaret G, Chung CS, et al.: PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci 106(150):6303-6308, 2009.
26. Riedemann NC, Neff TA, Guo RF, Bernacki KD, Laudes IJ, Sarma JV, Lambris JD, Ward PA: Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol 170:503-507, 2003. (Pubitemid 36026177)
27. Matsukawa A, Hogaboam CM, Lukacs NW, Lincoln PM, Strieter RM, Kunkel SL: Endogenous monocyte chemoattractant protein-1 (MCP-1) protects mice in a model of acute septic peritonitis: cross-talk between MCP-1 and leukotriene B4. J Immunol 163:6148-6154, 1989.
28. Ramnath RD, Ng SW, Guglielmotti A, Bhatia M: Role of MCP-1 in endotoxemia and sepsis. Int Immunopharmacol 8:810-818, 2008.
29. Sarkar FH, Li Y, Wang Z, Kong D: NF-kappaB signaling pathway and its therapeutic implications in human diseases. Int Rev Immunol 27(5):293-319, 2008.
30. Reville K, Crean JK, Vivers S, Dransfield I, Godson C: Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes. J Immunol 176(3):1878-1888, 2006. (Pubitemid 43134333)
31. Wu SH, Lu C, Dong L, Zhou GP, He ZG, Chen ZQ: Lipoxin A4 inhibits TNF-alphaYinduced production of interleukins and proliferation of rat mesangial cells. Kidney Int 68(1):35-46, 2005. (Pubitemid 43181362)
32. Jozsef L, Zouki C, Petasis NA, Serhan CN, Filep JG: Lipoxin A4 and aspirintriggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-.B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci USA 99:13266-13271, 2002.
33. Leonard ML, Hannah K, Burne MJ, Lappin DWP, Doran P, Coleman P, Stenson C, Taylor CT, Daniels F, Godson C, et al.: 15-Epi-16-(para-fluorophenoxy)- lipoxin A4-methyl ester, a synthetic analogue of 15-epi-lipoxin A4, is protective in experimental ischemic acute renal failure. J Am Soc Nephrol 13:1657-1662, 2002. (Pubitemid 34579255)
34. Jin SW, Zhang L, Lian QQ, Liu D, Wu P, Yao SL, Ye DY: Posttreatment with aspirin-triggered Lipoxin A4 analog attenuates lipopolysaccharide-induced acute lung injury in mice: the role of heme oxygenase-1. Crit Care Trauma 104(2):369-377, 2007. (Pubitemid 46146744)
35. Maddox JF, Serhan CN: Lipoxin A4 and B4 are potent stimuli for human monocyte migration and adhesion: selective inactivation by dehydrogenation and reduction. J Exp Med 183(1):137-146, 1996.